… andexanet alfa in patients with acute major bleeding occurring within 18 hours after their last
dose of factor Xa … from baseline in anti-factor Xa activity after andexanet alfa treatment and …

… oral anticoagulants (DOACs), including factor Xa … of andexanet alfa, a specific reversal
agent for FXai [10]. In the prospective, single-arm ANNEXA-4 study, treatment with andexanet alfa …

… Andexanet alfa is a modified human factor Xa decoy protein that binds and sequesters
factor Xa … There was a 92% reduction in median anti-factor Xa activity after andexanet alfa …

… reversal; and andexanet-alfa (following FDA approved dosage) for the reversal of FXa-inhibitor
associated … Full study report of andexanet alfa for bleeding associated with factor Xa …

… inhibitor-associated bleeding in most cases and a low thromboembolic … Andexanet alfa
was recently approved for the management of bleeding associated with the direct factor Xa …

… antidotes idarucizumab and andexanet alfa compared with … and andexanet alfa following
factor Xa inhibitor-associated ICH, … antidotes, idarucizumab, and andexanet alfa. The ANNEXA-…

… use of andexanet alfa for reversing factor Xa inhibitors in an … andexanet alfa provides
compared with placebo in achieving hemostasis is unclear. Additionally, decreases in anti-factor Xa …

… -AF and ARISTOTLE for the Factor Xa (FXa) inhibitors apixaban and … as ICH, frequently
warrant reversal of these anticoagulants. … recommend andexanet alfa for FXa inhibitor-associated …

… Andexanet alfa reverses edoxaban-induced anticoagulation in … A phase 2 PK/PD study of
andexanet alfa for reversal of … of andexanet alfa in patients with factor Xa inhibitor associated …

… ) on oral anticoagulants often require rapid reversal. This study evaluated patients taking …
andexanet alfa for reversal of factor Xa inhibitor-associated bleeding [6,7]. Andexanet alfa was …